论文部分内容阅读
钌配合物作为抗癌药物的研究已经受到了国际研究者的广泛关注。近年来,新型结构钌配合物的设计合成;钌配合物在细胞凋亡、信号传递、基因、蛋白表达等过程中的调控作用成为新的研究热点,金属钌配合物抗癌活性机制得到进一步的阐释。本文主要对钌配合物诱导肿瘤细胞凋亡及其信号通路以及蛋白调控等抗肿瘤机制的研究进行评述。主要包括:已经进入临床(Ⅰ、Ⅱ)期的抗癌钌配合物的抗肿瘤机制;钌配合物阻滞肿瘤细胞周期;通过内源性线粒体损伤、内质网应激等信号转导通路诱导肿瘤细胞凋亡,调节肿瘤细胞凋亡途径中相关蛋白的表达;调控与细胞凋亡或增殖相关蛋白酶类的表达和活性等。
The research of ruthenium complexes as anticancer drugs has attracted wide attention from international researchers. In recent years, the new structure of ruthenium complex design and synthesis; ruthenium complexes in apoptosis, signal transduction, gene, protein expression and other regulatory role has become a new research hot spot, the metal ruthenium complex antitumor activity mechanism was further Explain. This article reviews the research on the antitumor mechanisms induced by ruthenium complexes, such as apoptosis, signal pathway and protein regulation. Mainly include: antitumor mechanism of anticancer ruthenium complexes that have entered the clinical stage (Ⅰ, Ⅱ); ruthenium complexes block tumor cell cycle; induced by endogenous mitochondrial damage, endoplasmic reticulum stress and other signal transduction pathways Tumor cell apoptosis, regulation of tumor cell apoptosis pathway related protein expression; regulation and apoptosis or proliferation associated protease class of expression and activity.